In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG) by Liu, Zhendong et al.
Int. J. Mol. Sci. 2011, 12, 2650-2663; doi:10.3390/ijms12042650 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by 
Different Polyethylene Glycols (PEG) 
Zhendong Liu, Yinling Ren, Li Pan and Han-Mei Xu * 
Department of Marine Pharmacy, College of Life Science and Technology, China Pharmaceutical 
University, Nanjing 210009, China; E-Mails: liuzhendong0403@163.com (Z.L.); 
renyinling123@126.com (Y.R.); panli0225@163.com (L.P.) 
*  Author to whom correspondence should be addressed; E-Mail: xuhanmei@yahoo.com.cn;  
Tel.:+086-025-832-710-07; Fax: +086-025-835-625-76. 
Received: 12 February 2011; in revised form: 8 March 2011 / Accepted: 1 April 2011 /  
Published: 19 April 2011 
 
Abstract:  HM-3, designed by our laboratory, is  a polypeptide composed of 18 amino 
acids. Pharmacodynamic studies in vivo and in vitro indicated that HM-3 could inhibit 
endothelial cell migration and angiogenesis, thereby inhibiting tumor growth. However, the 
half-life of HM-3 is short. In this study, we modified HM-3 with different polyethylene 
glycols (PEG) in order to reduce the plasma clearance rate, extend the half-life in the body, 
maintain  a  high  concentration  of  HM-3  in  the  blood  and  increase  the  therapeutic 
efficiency. HM-3 was modified with four different types of PEG with different molecular 
weights  (ALD-mPEG5k,  ALD-mPEG10k,  SC-mPEG10k  and  SC-mPEG20k),  resulting  in  four 
modified  products  (ALD-mPEG5k-HM-3,  ALD-mPEG10k-HM-3,  SC-mPEG10k-HM-3  and 
SC-mPEG20k-HM-3, respectively). Anti-tumor activity of these four modified HM-3 was 
determined  in  BALB/c  mice  with  Taxol  as  a  positive  control  and  normal  saline  as  a 
negative  control.  Tumor  weight  inhibition  rates  of  mice  treated  with  Taxol,  HM-3, 
ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, SC-mPEG10k-HM-3 and SC-mPEG20k-HM-3 
were  44.50%,  43.92%,  37.95%,  31.64%,  20.27%  and  50.23%,  respectively.  Tumor 
inhibition  rates  in  the  Taxol,  HM-3  and  SC-mPEG20k-HM-3  groups  were  significantly 
higher than that in the negative control group. The efficiency of tumor inhibition in the 
SC-mPEG20k-HM-3 group (drug treatment frequency: once per two days) was better than 
that  in  the  HM-3  group  (drug  treatment  frequency:  twice  per  day).  In  addition,  tumor 
inhibition rate in the SC-mPEG20k-HM-3 group was higher than that in the taxol group. We 
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conclude  that  SC-mPEG20k-HM-3  had  a  low  plasma  clearance  rate  and  long  half-life, 
resulting in high anti-tumor therapeutic efficacy in vivo. Therefore, SC-mPEG20k-HM-3 
could be potentially developed as new anti-tumor drugs. 
Keywords: PEG modification; peptides; HM-3; anti-tumor; activities 
Abbreviations: ALD-mPEG (methoxy-polyethylene glycol propionaldehyde); molecular weight 
10 kDa; named ALD-mPEG10k; SC-mPEG (α-methoxy-polyethylene glycol-ω-Succinimidyl 
Carbonate); molecular weight 20 kDa, named SC-mPEG20k 
 
1. Introduction 
HM-3 is a new anti-tumor polypeptide developed in our laboratory, which is composed of 18 amino 
acids and previous studies showed that the target of HM-3 is integrin (αvβ3) [1]. In vivo and in vitro 
studies  have  shown  that  HM-3  could  inhibit  endothelial  cell  migration  and  angiogenesis,  thereby 
inhibiting tumor growth. HM-3 is expected to be developed as therapeutic drugs for the treatment of 
solid tumors including gastric and liver cancer [2]. HM-3 has been authorized as a national invention 
patent and declared for an international patent [3]. 
However, similar to other peptide drugs, the half-life of HM-3 is short (approximately 25 min). 
HM-3 is easily degraded by proteases [1,4]. Animal studies suggested that the optimal therapeutic 
efficiency could be obtained by administration of the drug twice a day.  
An effective approach to solve this problem is to modify peptide drugs with polymers such as 
polyethylene  glycol  (PEG)  and  dextran  [5].  Currently,  most  studies  are  focusing  on  PEG 
modification [6–8]. PEG is a class of large polymers with unique physical and chemical properties. PEG 
is non-toxic, non-antigenic and has good biocompatibility [9,10]. The main biological function of 
PEG-modified  protein  or  peptide  drugs  remains  unchanged.  More  importantly,  PEG  modification 
increases the circulatory stability, extends the half-life, reduces the immunogenicity and decreases the 
toxcity of protein or peptide drugs [11–14].  
However, PEG modification still exhibits several problems in application. Based on the literature [9,10], 
the main problems associated with PEG modification were an abnormal increase of molecular weight 
of the modified products and a decrease or loss of activity during the process of modification. Loss of 
activity  is  essentially  the  primary  problem  that  needs  to  be  solved  for  PEG  modification  of 
peptide drugs [15,16]. 
Selection of the appropriate molecular size of PEG is key for the modification of peptide drugs. 
Two main considerations for selecting the type of PEG are the residual in vivo biological activity and 
the renal elimination rate of the modified products. The molecular size of PEG is negatively related to 
the residual biological activity of the peptide drugs [17]. The relationship between the size of PEG and 
renal elimination rate is that a larger size of PEG normally results in a lower renal elimination rate. 
Studies have shown that the renal elimination rate when using PEG with a molecular weight of 20 kDa Int. J. Mol. Sci. 2011, 12                       
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is  approximately  10%,  which  plays  a  significant  role  in  increasing  the  half-life,  extending  drug 
administration  frequency  and  maintaining  the  blood  drug  concentration  at  a  high  level  [18,19]. 
Currently, a variety of PEG-modified protein and peptide drugs have been developed and approved by 
the FDA for biomedical purposes [20]. 
ALD-mPEG  and  SC-mPEG  are  two  different  types  of  PEG,  which  are  currently  the  most 
commonly used and relatively mature with active groups to modify polypeptide drugs. The active 
groups of ALD-mPEG and SC-mPEG are propionaldehyde and succinimidyl carbonate, respectively, 
which are specificity reactive groups of the peptide’s end amino. Physical properties, reaction activity 
with  the  peptide’s  end  amino  of  ALD-mPEG  and  SC-mPEG  were  different,  and  the  remaining 
bioactivity of the same peptide PEGylated by the different two PEG were different too. A previous 
study [1] reported that HM-3 modified with ALD-mPEG10k showed improved half-life and biological 
activity in vitro, but the half-life improvement was not significant. 
In order to solve the problem of short half-life and rapid plasma clearance, our laboratory utilized 
four different types of PEG (ALD-mPEG and SC-mPEG) with different molecular weights to modify 
the N-terminus of HM-3. We expected that the modified products would have a long half-life while 
maintaining the anti-tumor activity. Our results showed that the modified product, SC-mPEG20k-HM-3, 
had a low plasma clearance rate, long half-life and retained its anti-tumor activity excellently. These 
results provide a fundamental basis for the development of new anti-tumor drugs. 
2. Materials and Methods 
2.1. Materials 
2.1.1. Cell Line and Animals 
Human  hepatic  carcinoma  SMMC-7721  cell  line  was  purchased  from  American  type  Cell 
Culture (ATCC, Shanghai, China) and maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 
10% fetal bovine serum and antibiotics. BALB/c nude female mouse (SPF grade, 4–5 w, 20.9 ±  0.492 g) 
were purchased from the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences.  
2.1.2. Main Reagents and Drugs 
ALD-mPEG5k (98% purity), ALD-mPEG10k (100% purity), SC-mPEG10k (98% purity), and 
SC-mPEG20k  (100%  purity)  were  purchased  from  Beijing  Kaizheng  Biotech  Development 
Co. Ltd. Batch No. were KZ-M05ALD-091207, KZ-M10ALD-091208, KZ-M10SC-091205, and 
KZ-M20SC-091206, respectively. 
Triﬂuoroacetate (TFA), acetonitrile (ACN), and sodium cyanoborohydride were purchased from 
TEDIA, ROE Scientiﬁc Inc., and Shanghai Darui Fine Chemicals Co. Ltd, respectively. 
HM-3 was chemically synthesized by GL Biochem (Shanghai), Ltd. The purity of the products was 
more than 99% by analytical high-performance liquid chromatography (HPLC), Batch No. 091020. Int. J. Mol. Sci. 2011, 12                       
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Mouse anti-HM-3 monoclonal antibody was prepared in our laboratory (density: 1.19 mg/mL, 
tite: 2,048,000). Horseradish peroxidase-labeled goat anti-mouse secondary antibody was purchased 
from Boster Biological Company of China. 
Docetaxel was purchased from Hengrui Medicine Co. Ltd, Jiangsu province of China, Batch 
No. 10012812.  
2.2. Methods 
2.2.1. PEG Modification of HM-3 and Purification 
The  forms  of  PEG  modified  HM-3  and  the  optimal  conditions  have  been  systematically 
studied [1,4,21]. As to the modification of HM-3 with ALD-mPEG5k and ALD-mPEG10k, the optimal 
reaction time was over night at 4 °C ; whereas the optimal time for SC-mPEG10k and SC-mPEG20k 
was 3 h at 4 °C . After the modification experiments, the products were purified by a semipreparative 
RP-HPLC and the purity  was  detected with  analytical  RP-HPLC. The  reaction buffers and molar 
ratios (PEG:HM-3) are shown in Table 1. 
Table 1. HM-3, conditions of polyethylene glycol (PEG) modification. 
Phosphate  Buffers, 
PBS (pH) 
PEG  mol Ratio 
（PEG:HM-3） 
Modification 
Rate 
PBS 5.0  ALD-mPEG5k  2:1  69.61% 
PBS 5.0  ALD-mPEG10k  2.5:1  88.41% 
PBS 8.0  SC-mPEG10k  1.5:1  95.94% 
PBS 8.5  SC-mPEG20k  1.5:1  96.84% 
2.2.2. SDS-PAGE Electrophoresis and Western Blot Analysis of the Modified Products  
Reaction mixtures were separated on a SDS-PAGE gel which was comprised of a 5% stacking gel 
and a 10% separation gel. The lane of the marker was stained with  Coomassie brilliant blue and the 
lanes for ALD-mPEG5k-HM-3,  ALD-mPEG10k-HM-3,  SC-mPEG10k-HM-3  and  SC-mPEG20k-HM-3 
were stained with BaI2. 
After SDS-PAGE electrophoresis, ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, SC-mPEG10k-HM-3 
and SC-mPEG20k-HM-3 were further identiﬁed by Western blot analysis using nitrocellulose membranes. 
The immunological reaction of ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, SC-mPEG10k-HM-3 and 
SC-mPEG20k-HM-3 were performed on sections using a speciﬁc mouse anti-HM-3 monoclonal antibody 
of  high titer  and speciﬁcity and subsequently with horseradish  peroxidase-labeled  goat anti-mouse 
secondary antibody. Immunodetection was visualized using enhanced chemiluminescence. 
2.2.3. Inhibitory Effect of the Modified Products on the Growth of Human Hepatoma Cells in Vivo 
SMMC-7721 cells were cultured in DMEM medium under 5% CO2/saturated humidified air at 
37 ° C. Cells were digested with the mixture of the trypsin (0.25%) and EDTA (0.02%) at logarithmic Int. J. Mol. Sci. 2011, 12                       
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growth phase and passaged every 3–4 day. Then SMMC-7721 cells at logarithmic growth phase were 
digested to make a cell suspension (1.0 ×  10
7/mL), and 0.1 mL was injected into axilla of the left arm 
of  BALB/c  nude  mouse.  When  tumor  volume  grew  to  50  mm
3–60  mm
3,  the  mice  were  divided 
into 7 groups  with  6  in  each  group.  The  doses  and  frequencies  of  drug  administration  are 
presented in Table 2 for the groups of paclitaxel, HM-3, ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, 
SC-mPEG10k-HM-3 and SC-mPEG20k-HM-3. 
All the mice (20 g) were administrated intravenously for 21 days and the tumor volumes were 
measured every two days. The solid tumor tissues were taken out the next day after the administration 
menu and the tissues were weighed to determine the inhibitory effects of the modified products. The 
calculation formula of tumor volume (TV) was as follows [22]: TV = 0.52 ×  a ×  b
2, a and b indicate tumor 
length and width, respectively. Antitumor ratio determined by the tumor volumes is (V − Vt)/V (V is the 
average tumor volume of the control group, and Vt is the average tumor volume of the treated group). 
The antitumor ratio by the tumor weights was also calculated as (W − Wt)/W (W is the average tumor 
weight of the control group, and Wt is the average tumor weight of the treatment group).  
Table 2. Dosage and frequency of drugs. 
Groups  Drugs  Frequency  Dosage 
First 
Second 
Third 
Fourth 
Control 
Taxol 
HM-3 
ALD-mPEG5k-HM-3 
once a day  
twice a week  
twice a day 
once a day 
0.2 mL/d 
10 mg/kg 
3 mg/(kg· d) 
11.4 mg/(kg· d) 
Fifth 
Sixth 
ALD-mPEG10k-HM-3 
SC-mPEG10k-HM-3 
every two days  
every two days 
19.9 mg/(kg· 2d) 
19.9 mg/(kg· 2d) 
Seventh  SC-mPEG20k-HM-3  every two days  36.7 mg/(kg· 2d) 
Annotation: PEG-HM-3 dosage is total PEG conjugate. 
2.2.4. Statistical Methods 
The data was analyzed using the statistics software SPSS13.0, which are expressed as mean ± SD. 
Statistical signiﬁcance was assessed using the Student t test. For all statistical comparisons, treated 
groups were compared with normal sodium treated controls, and P < 0.05 was considered statistically 
signiﬁcant; P < 0.01 was considered statistically very signiﬁcant. 
3. Results 
3.1. Purity of the Four Modified HM-3 Products 
RP-HPLC  analysis  showed  that  the  purity  of  the  four  PEG-modified  HM-3  products  
(ALD-mPEG5k-HM-3, ALD-mPEG10k- HM-3, SC-mPEG10k-HM-3 and SC-mPEG20k-HM-3) was over 
97% (Figure 1). 
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Figure 1. RP-HPLC analysis of PEGylated HM-3. Analysis was performed on a C18 column 
with water/ACN/TFA as eluent and a flow rate of 1 mL/min, and peaks were monitored at 
220 nm. (A) ALD-mPEG5k-HM-3 purity: 97.39%, T: 9.395 min; (B) ALD-mPEG10k-HM-3 
purity: 98.23%, T: 9.698 min; (C) SC-mPEG10k-HM-3 purity: 97.02%, T: 9.883 min; 
(D) SC-mPEG20k-HM-3 purity: 98.52%, T: 9.578 min.  
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Figure 1. Cont. 
 
3.2. SDS-PAGE and Western Blot Analysis of the Modified HM-3 Products 
Modification of HM-3 with mPEG resulted in mPEG-HM-3 with relatively high purity. SDS-PAGE 
analysis showed that the Mr of the modified product mPEG-HM-3 was much higher than that of the 
sum of HM-3 and mPEG (Figure 2). This could be due to the following two reasons. Firstly, linear 
PEG could extend on the surface of the protein, reducing the protein migration rate. Secondly, PEG 
had a very high degree of hydration, which increased its molecular size and reduced the migration rate 
in SDS-PAGE. We also found that monoclonal antibody binding site of the modified HM-3 were not 
covered by mPEG, which may be favorable for the maintenance of anti-tumor activity (Figure 3). 
Figure  2.  SDS-PAGE  analysis  of  PEGylated  HM-3.  Lane  Marker,  Molecular  weight 
markers; Lane 1, SDS-PAGE of SC-mPEG20k; Lane 2, SDS-PAGE of SC-mPEG20k-HM-3; 
Lane 3, SDS-PAGE of SC-mPEG10k; Lane 4, SDS-PAGE of SC-mPEG10k-HM-3; Lane 5, 
SDS-PAGE  of  ALD-mPEG10k;  Lane  6,  SDS-PAGE  of  ALD-mPEG10k-HM-3;  Lane  7, 
SDS-PAGE of ALD-mPEG5k; Lane 8, SDS-PAGE of ALD-mPEG5k-HM-3. 
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Figure  3.  Western  Blot  analysis  of  PEGylated  HM-3.  (I)  SC-mPEG20k-HM-3; 
(II) SC-mPEG10k-HM-3; (III) ALD-mPEG10k-HM-3; (IV) ALD-mPEG5k-HM-3. 
 
3.3. Anti-Tumor Activity of the Different PEG-Modified HM-3 
We treated nude mouse with HM-3, ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, SC-mPEG10k-HM-3 
and SC-mPEG20k-HM-3 and determined the tumor growth. Taxol was used as a positive control. We 
found that tumor growth in the HM-3 and SC-mPEG20k-HM-3 groups was significantly slower than 
that in the Taxol group. In addition, tumor growth in the HM-3 group and SC-mPEG20k-HM-3 group 
was  significantly  different  from  that  in  the  negative  control  group  (P  <  0.05  and  P  <  0.01, 
respectively) (Figure 4).  
Figure 4. Therapeutic effects of peptides on the growth of tumors in BALB/c nude mice. 
Each point represents mean ±  SD of each group (mean ±  SD, n = 6, *P < 0.05; **P < 0.01 
versus control). Control, once a day; The positive control drug Taxol at the dose of 10 
mg/kg twice a week; HM-3 at the dose of 3 mg/kg twice a day; ALD-mPEG5k-HM-3 at the 
dose of 11.4 mg/kg once a day; ALD-mPEG10k-HM-3 at the dose of 19.9 mg/kg once every 
2 day; SC-mPEG10k-HM-3 at the dose of 19.9 mg/kg once every 2 days; SC-mPEG20k-HM-3 
at the dose of 36.7 mg/kg once every 2 day. 
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Tumor  inhibitory  rate  in  the  SC-mPEG20k-HM-3  group  (50.23%)  and  HM-3  group  (43.92%) 
were  similar to that in the Taxol group (44.50%), indicating that SC-mPEG20k-HM-3 maintained its 
anti-tumor  activity.  Tumor  inhibitory  rate  in  the  ALD-mPEG5k-HM-3  and  ALD-mPEG10k-HM-3 
groups was 37.95% and 31.64%, respectively. Tumor weight in SC-mPEG20k-HM-3, HM-3 or Taxol 
groups was significantly different from that in the negative group (P < 0.05) (Figures 5 and 6). Photographs 
of the tumors at the end of the study are shown in Figure 7, tumors in the SC-mPEG20k-HM-3, HM-3 
or Taxol groups were significantly different from that in the negative group. The body weight of nude 
mice in each group was stable (20–25 g), and was similar between different groups. Rapid increase or 
decrease of body weight did not occur (Figure 8). 
Figure 5. Average tumor weight in BALB/c nude mice. The data was analyzed using the 
statistics software SPSS13.0. Columns represent mean ±  SD of each group (mean ±  SD, 
n = 6, *P < 0.05 versus control). 
 
Figure 6. Inhibition rate of average tumor weight in BALB/c nude mice (n = 6).  
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Figure 7. Photos of tumors at the end of the study indicating the therapeutic effects of 
peptides in BALB/c nude mice (n = 6). 
 
Figure 8. Weight change of BALB/c nude mice. Results are expressed as mean ±  SD per 
group (mean ±  SD, n = 6). 
 
4. Discussion 
It  is  well  known  that  attachment  of  polyethylene  glycol  (PEG)  to  therapeutic  peptides  or 
proteins (referred  to  as  PEGylation)  effectively  prolongs  their  half-lives,  reduces  antigenicity  and 
immunogenicity, and improves their pharmacokinetic and pharmacodynamic properties, rendering the 
drugs significantly prolonged circulating half-lives [23,24]. 
SC-mPEG (mPEG-succinimidyl carbonate) and ALD-mPEG (mPEG-propionaldehyde) have been 
the  most  commonly  used  chain-shaped  PEG  with  active  groups.  Urethane  bonds  generated  after 
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coupling between SC-mPEG and peptides, and secondary amine generated after combining ALD-mPEG 
and peptides, are more stable and have a higher hydrolytic stability than ester bonds [25,26]. The 
SC-mPEG was extremely reactive, with reactions with peptides or proteins requiring higher pH in 
PBS, while the ALD-mPEG required mild reaction conditions, and could combine with peptides or 
proteins in mild pH in PBS [27]. Yet, the reactivity of the latter was lower than the former using the 
same peptides or proteins.  
In PEGylation of pharmaceuticals, the design of an appropriate conjugation strategy is essential to 
confer the desired properties to the parent peptide or protein. The random conjugation of PEG would 
result in significant decrease, even loss of bioactivities, which showed inconsistent therapeutic effects 
and was undesired in PEGylated pharmaceuticals [20,28,29]. 
Therefore,  when  we  modify  a  molecule  with  PEG,  we  should  choose  PEGs  that  have  optimal 
balance between  the  activity  maintaining  rate  and  their  half-life  in  vivo.  According  to  previous 
studies, the in vitro activity of the PEGylated HM-3 products (especially SC-mPEG20k-HM-3) were high, 
but the in vivo activity was not measured. Thus, it is necessary to study the in vivo activity of the 
PEGylated HM-3 [1,4]. 
Figure 6 shows that the activity maintaining rate of modification by SC-mPEG10k and ALD-mPEG10k 
were not high, and the tumor inhibition rate of  SC-mPEG10k-HM-3 (20.27%) was lower than 
ALD-mPEG10k-HM-3  (31.64%),  while  the  modified  product  of  SC-mPEG20k-HM-3  (50.23%)  was 
excellent, displaying similar tumor inhibitory activity in vivo to the Taxol and unmodified HM-3 groups. 
Generally speaking, modification with large molecule PEG may result in reduced activity. The 
activity of modified products of anti-tumor peptides and proteins is closely associated with organism 
resistance, PEG mass and shape, stability of PEG-peptide or PEG-protein bond, and changes in the 
spatial structure of modified products [27,30].  
In our study, the activity of SC-mPEG20k-HM-3 did not change. This might be due to the fact that 
the loss of biological activity was compensated for by the significantly prolonged half-life and blood 
plasma residence time in vivo, as a result of the increased stability and higher hydrodynamic volume 
after modification. The activity of ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, and SC-mPEG10k-HM-3 
would decline with different degrees after modification, while the half-life and blood plasma residence 
time of these in vivo were low, which were not obviously prolonged in the previous study. Perhaps 
these factors cause the anti-tumor activity of  ALD-mPEG5k-HM-3, ALD-mPEG10k-HM-3, and 
SC-mPEG10k-HM-3 to be lower than SC-mPEG20k-HM-3 and unmodified HM-3 in vivo. Besides, 
the  active  groups  of  SC-mPEG  and  ALD-mPEG  are  different,  coupling  between  SC-mPEG  and 
peptides with urethane bond, and in the presence of sodium cyanoborohydride, a secondary amine 
would be generated after combination of ALD-mPEG and peptides. The latter stability was higher 
than the former in vivo [31,32]. Maybe this led to the different activity of SC-mPEG10k-HM-3 and 
ALD-mPEG10k-HM-3 in vivo. 
SC-mPEG20k-HM-3 retained the original biological activity of HM-3. Tumor inhibition of 
SC-mPEG20k-HM-3 (50.23%) was slightly higher than that of Taxol in vivo. These data suggest that 
the  half-life  of  HM-3  can  be  improved  by  modification  with  SC-mPEG20k.  For  instance,  drug Int. J. Mol. Sci. 2011, 12                       
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administration frequency was extended from twice per day to once per two days after modification 
by SC-mPEG20k. The anti-tumor therapeutic efficacy of SC-mPEG20k-HM-3 was more efficient than 
that of HM-3. The body weight of mice in each group was maintained at a stable level, indicating 
that the effective dosage of drugs is non-toxic or the toxicity is low.  
Therefore, this study demonstrated that SC-mPEG20k can be used for modification of HM-3 and 
further determined in vivo biological activity of the modified product SC-mPEG20k-HM-3. We will 
further characterize the physio-chemical properties, in vivo pharmacokinetics, immunogenicity and the 
antitumor target of SC-mPEG20k-HM-3.  
Our preliminary results found that although the tumor grew slowly and the tumor formation rate 
was low in nude mice inoculated with 5 ×  10
5 tumor cells/mice, administration of drugs had a good 
effect in inhibiting the tumors. The tumor inhibition for small tumors (20 mm
3–30 mm
3) was more 
efficient than for large tumors (>80 mm
3). Taxol administered once per two days (10 mg/kg/time) had 
better tumor inhibition than that administered twice per week. However, Taxol is highly toxic and 
frequent administration of taxol may result in weight loss or even death. Thus, in this study, we treated 
the mice with Taxol twice per week. In addition, if the tumor cell line was transferred in culture too 
many  times,  the  property  of  the  cells  may  be  changed,  which  may  affect  the  evaluation  of  the 
therapeutic efficiency. These results provide references for other related studies. 
5. Conclusion 
SC-mPEG20k-HM-3  retained  the  anti-tumor  activity  of  HM-3  better  than  other  PEG-modified 
products. In addition, SC-mPEG20k modified peptide HM-3 had a low plasma clearance rate, long 
half-life and retained its anti-tumor activity. Therefore, SC-mPEG20k-HM-3 has a very high value for 
development of new anti-tumor drugs. 
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